Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
42 hedge funds and large institutions have $349M invested in Dicerna Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$96.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$90.2M |
| 3 |
DM
Deerfield Management
New York
|
+$90.2M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$56.2M |
| 5 |
A
Abingworth
London,
United Kingdom
|
+$43.9M |
Top Sellers
DRNA Hedge Fund Activity: Q1 2014 in Review
42 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2014, worth a combined $349M.
Buyers outnumbered sellers: 42 funds opened new DRNA positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $96.7M.
- 42 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $349M of Dicerna Pharmaceuticals, Inc. stock for Q1 2014.
- 42 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2014 and 0 closed out, a net change of +42 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $96.7M added.
Based on aggregated 13F filings for Q1 2014.